James -
Kids basketball.
Below is a summary of the various past projections vs. Actual.
================================================================
BrookeHill Equities
97
E.P.S.
-----
YTD = $1.21
4th = .19
----
Year $1.40
====
================================================================
Revised
4th Qtr. 1997
BIOX
Revised BrkHil Q4
IBD JM JM Equiti Act
----- ----- ----- ----- -----
Sy3 - AHP - USA 3,600 5,000 3,600 5,300 6,247
Sy3 - AHP - Foreign 500 250 250 250
Sy3 - BI - France 0 250 250 250
Sy3 - RPR - Canada 567 450 450 450
Sy3 - Roche - Sweden 500 250 250 250
Hylaform - CGEN - Foreig 200 450 450 450
Hylashied - Italy 0 25 25 25
Other - Cosmetic 0 325 325 325
----- ----- ----- ----- -----
Total Product Sales 5,367 7,000 5,600 7,300 6,247
----- ----- ----- ----- -----
AHP Fee Payment 0 1,000 1,000 1,000 1,439
----- ----- ----- ----- -----
Total Payments 0 1,000 1,000 1,000 1,439
----- ----- ----- ----- -----
Total Net Revenues 5,367 8,000 6,600 8,300 7,686
----- ----- ----- ----- -----
Product GM (Avg. %) 0.68 0.68 0.68 0.68 0.73
Product GM$ 3,650 4,760 3,808 4,964 4,548
License GM$ 0 1,000 1,000 1,000 1,439
----- ----- ----- ----- -----
Total GM$ 3,650 5,760 4,808 5,964 5,987
----- ----- ----- ----- -----
R&D 1,575 1,575 1,575 1,575 1,590
G&A 2,150 2,150 2,150 2,150 2,586
----- ----- ----- ----- -----
Total Operations Expen 3,725 3,725 3,725 3,725 4,176
----- ----- ----- ----- -----
----- ----- ----- ----- -----
Income from Operations -75 2,035 1,083 2,239 1,811
----- ----- ----- ----- -----
Interest/Other Inc 190 190 190 190 402
----- ----- ----- ----- -----
EBT 115 2,225 1,273 2,429 2,213
----- ----- ----- ----- -----
Tax Provision % 0.1 0.1 0.1 0.1 0.1
Tax Provision $ 11 223 127 243 216
----- ----- ----- ----- -----
EAT 104 2,002 1,146 2,186 1,997
===== ===== ===== ===== =====
E.P.S (Diluted) 0.01 0.17 0.10 0.19 0.17
===== ===== ===== ===== =====
Shares Out 11,500 11,500 11,500 11,500 11,538
===== ===== ===== ===== =====
I'm like Rich - I don't understand the reaction.
It maybe like pkwknk said, LACK OF COMMENTS about various issues.
Nonetheless, I've decided to shut up for the next 2 weeks and
see if this doesn't POP UP on some mutual fund screens and/or
broker recommendations.
Remember - 1st Qtr 98 results are only 7 weeks away *from being
reported*
Can't prove it, but I just don't think there are any
Revenue issues - from a user wants the product perspective.
James, I'm confused about something. Is BIOX shipping product
from their AMERICAN facility or the CANADIAN facility?
Somewhere along the line, I thought the AMERICAN facility was
up and running, but today's comments did not imply that.
With respect to the numbers, the high/low points were:
(1) GM% is a whopping 5% (thats 5 points in finance jargon)
better than expected.
(2) We got creamed with about $500 EXTRA of G&A cost
this quarter. THATS ALOT OF MONEY FOR THE QUARTER.
Was it for
(a) bonus accruals,
(b) costs associated with the failure of the Hylaform thingie
(c) U.K. setup costs
(d) new people on board, etc. i.e. VP Finance
and more importantly, does it suggest that G&A costs will
average $500 higher a Qtr. than previously thought.
In any event, it was a big, bad surprize.
(3) I have NO IDEA what the $402 in other income is.
Figure maybe $200 for interest income, but don't know
what the rest ($202) was for.
(4) I had hoped they'd split out the AHP sales. My best guess
is that the AMERICAN AHP sales were about $4,200. This
guess is out of my ..... but I suspect it is in the ballpark.
Regards,
John |
